Donor type, in addition to transplantation in chronic phase and myeloablative conditioning, influence transplant survival for patients with advanced chronic myeloid leukemia in the era of tyrosine kinase inhibitors
Details
The content you want is available to Zendy users.Already have an account? Click here. to sign in.